Subscribe
ftc
parbradyphoto / iStockphoto.com
19 December 2018Big Pharma

FTC agrees to re-open Actavis and Watson merger decision

The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva settles Sensipar patent dispute with Amgen
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
Teva and FTC reach settlement over ‘pay-for-delay’
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
Americas
FTC launches pharma merger analysis group
18 March 2021   The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
Teva settles Sensipar patent dispute with Amgen
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
Teva and FTC reach settlement over ‘pay-for-delay’
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
Americas
FTC launches pharma merger analysis group
18 March 2021   The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.

More on this story

Big Pharma
Teva settles Sensipar patent dispute with Amgen
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
Teva and FTC reach settlement over ‘pay-for-delay’
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
Americas
FTC launches pharma merger analysis group
18 March 2021   The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility